Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Bacterial Metabolism and Antibiotic Efficacy.

Stokes JM, Lopatkin AJ, Lobritz MA, Collins JJ.

Cell Metab. 2019 Aug 6;30(2):251-259. doi: 10.1016/j.cmet.2019.06.009. Epub 2019 Jul 3. Review.

PMID:
31279676
2.

Understanding and Sensitizing Density-Dependent Persistence to Quinolone Antibiotics.

Gutierrez A, Jain S, Bhargava P, Hamblin M, Lobritz MA, Collins JJ.

Mol Cell. 2017 Dec 21;68(6):1147-1154.e3. doi: 10.1016/j.molcel.2017.11.012. Epub 2017 Dec 7.

3.

Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control.

Meylan S, Porter CBM, Yang JH, Belenky P, Gutierrez A, Lobritz MA, Park J, Kim SH, Moskowitz SM, Collins JJ.

Cell Chem Biol. 2017 Feb 16;24(2):195-206. doi: 10.1016/j.chembiol.2016.12.015. Epub 2017 Jan 19.

4.

Bactericidal Antibiotics Induce Toxic Metabolic Perturbations that Lead to Cellular Damage.

Belenky P, Ye JD, Porter CB, Cohen NR, Lobritz MA, Ferrante T, Jain S, Korry BJ, Schwarz EG, Walker GC, Collins JJ.

Cell Rep. 2015 Nov 3;13(5):968-80. doi: 10.1016/j.celrep.2015.09.059. Epub 2015 Oct 22.

5.

Antibiotic efficacy is linked to bacterial cellular respiration.

Lobritz MA, Belenky P, Porter CB, Gutierrez A, Yang JH, Schwarz EG, Dwyer DJ, Khalil AS, Collins JJ.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8173-80. doi: 10.1073/pnas.1509743112. Epub 2015 Jun 22.

6.

Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies.

Krom RJ, Bhargava P, Lobritz MA, Collins JJ.

Nano Lett. 2015 Jul 8;15(7):4808-13. doi: 10.1021/acs.nanolett.5b01943. Epub 2015 Jun 8.

PMID:
26044909
7.

Antibiotics induce redox-related physiological alterations as part of their lethality.

Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, Takahashi N, Chan CT, Lobritz MA, Braff D, Schwarz EG, Ye JD, Pati M, Vercruysse M, Ralifo PS, Allison KR, Khalil AS, Ting AY, Walker GC, Collins JJ.

Proc Natl Acad Sci U S A. 2014 May 20;111(20):E2100-9. doi: 10.1073/pnas.1401876111. Epub 2014 May 6.

8.

Microbial persistence and the road to drug resistance.

Cohen NR, Lobritz MA, Collins JJ.

Cell Host Microbe. 2013 Jun 12;13(6):632-42. doi: 10.1016/j.chom.2013.05.009. Review.

9.

Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Lobritz MA, Ratcliff AN, Marozsan AJ, Dudley DM, Tilton JC, Arts EJ.

Antimicrob Agents Chemother. 2013 Jun;57(6):2640-50. doi: 10.1128/AAC.02511-12. Epub 2013 Mar 25.

10.

A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.

Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC.

PLoS One. 2012;7(1):e30176. doi: 10.1371/journal.pone.0030176. Epub 2012 Jan 24.

11.

Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA.

Lalonde MS, Lobritz MA, Ratcliff A, Chamanian M, Athanassiou Z, Tyagi M, Wong J, Robinson JA, Karn J, Varani G, Arts EJ.

PLoS Pathog. 2011 May;7(5):e1002038. doi: 10.1371/journal.ppat.1002038. Epub 2011 May 19.

12.

HIV-1 replicative fitness in elite controllers.

Lobritz MA, Lassen KG, Arts EJ.

Curr Opin HIV AIDS. 2011 May;6(3):214-20. doi: 10.1097/COH.0b013e3283454cf5. Review.

13.

Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.

Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenröder O, Kräusslich HG, Arts EJ.

J Virol. 2010 Oct;84(19):9817-30. doi: 10.1128/JVI.00991-10. Epub 2010 Jul 14.

14.

Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.

Lassen KG, Wissing S, Lobritz MA, Santiago M, Greene WC.

J Biol Chem. 2010 Sep 17;285(38):29326-35. doi: 10.1074/jbc.M110.154054. Epub 2010 Jul 12.

15.

HIV-1 Entry, Inhibitors, and Resistance.

Lobritz MA, Ratcliff AN, Arts EJ.

Viruses. 2010 May;2(5):1069-105. doi: 10.3390/v2051069. Epub 2010 Apr 29.

16.

A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.

Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B.

J Virol. 2009 Nov;83(21):11016-26. doi: 10.1128/JVI.01242-09. Epub 2009 Aug 19.

17.

Viral fitness implications of variation within an immunodominant CD8+ T-cell epitope of HIV-1.

Christie NM, Willer DO, Lobritz MA, Chan JK, Arts EJ, Ostrowski MA, Cochrane A, Luscher MA, MacDonald KS.

Virology. 2009 May 25;388(1):137-46. doi: 10.1016/j.virol.2009.03.003. Epub 2009 Apr 15.

18.

Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics.

Lassen KG, Lobritz MA, Bailey JR, Johnston S, Nguyen S, Lee B, Chou T, Siliciano RF, Markowitz M, Arts EJ.

PLoS Pathog. 2009 Apr;5(4):e1000377. doi: 10.1371/journal.ppat.1000377. Epub 2009 Apr 10.

19.

Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response.

Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM, Zhao H, Avila S, Lobritz MA, McElrath MJ, Le Gall S, Mullins JI, Arts EJ.

PLoS Pathog. 2009 Apr;5(4):e1000365. doi: 10.1371/journal.ppat.1000365. Epub 2009 Apr 3.

20.

HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.

Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, Brander C, Toth I, Arts EJ, Allen TM, Walker BD.

J Virol. 2009 Mar;83(6):2743-55. doi: 10.1128/JVI.02265-08. Epub 2008 Dec 30. Erratum in: J Virol. 2009 Jun;83(11):5961.

21.

Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication.

Gao Y, Lobritz MA, Roth J, Abreha M, Nelson KN, Nankya I, Moore-Dudley DM, Abraha A, Gerson SL, Arts EJ.

J Virol. 2008 Mar;82(6):2938-51. doi: 10.1128/JVI.02126-07. Epub 2008 Jan 16.

22.

Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.

Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ.

J Virol. 2007 Aug;81(15):8258-69. Epub 2007 May 23.

23.

Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, Arts EJ.

J Virol. 2005 Jun;79(11):7121-34.

24.

Translocation and surface expression of lipidated serogroup B capsular Polysaccharide in Neisseria meningitidis.

Tzeng YL, Datta AK, Strole CA, Lobritz MA, Carlson RW, Stephens DS.

Infect Immun. 2005 Mar;73(3):1491-505.

25.

Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.

Lobritz M, Hutton-Thomas R, Marshall S, Rice LB.

Antimicrob Agents Chemother. 2003 Oct;47(10):3318-20.

26.

Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quiñones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, Zimmerman PA, Kawamura T, Blauvelt A, Arts EJ.

J Virol. 2003 Jan;77(2):1021-38.

Supplemental Content

Loading ...
Support Center